樂
樂觀
樂觀 · 25%APUS
$2.05
情境價格
$2.685
-0.044 (-1.65%)收盤時
Loading chart…
- 最高
- 2.752
- 開盤
- 2.670
- 成交量加權均價
- 2.66
- 成交量
- 15.08K
- 市值
- —
- 最低
- 2.530
- 成交金額
- 40.05K
- 企業價值/稅息折舊攤銷前利潤（TTM）
- 0.00
Apimeds Pharmaceuticals US, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in developing Apitox, an intradermally administered bee venom-based toxin. It is focused on developing Apitox in the treatment of inflammatory conditions in the United States, specifically osteoarthritis and multiple sclerosis. Its subsidiary, MindWave Innovations Inc, is a provider of institutional digital asset treasury (DAT) solutions.
AI 分析 of Apimeds Pharmaceuticals US Inc (APUS)
賣出Apimeds Pharmaceuticals US Inc is not a good buy right now due to its significant financial losses and poor technical indicators. The current price is $2.68, and the company has reported a staggering net income loss of $35,059,852 in Q1 2026. Additionally, the RSI is at 26.149, indicating that the stock is oversold, but this does not suggest a buying opportunity given the ongoing financial instability.
估值指標
Apimeds Pharmaceuticals US Inc（APUS）目前預期本益比為 0.00，5 年平均預期本益比為 0.00。
Alphio AI 對 APUS 的價格情境
情境價格取自當年最後一個月度預測區間。機率為固定的模型權重（25 / 50 / 25），不構成保證。
事件時間軸
資訊
8.510-13NewsfilterMindWave Lists NILA Token on Pionex Exchange
- 7.510-09Newsfilter
MindWave Signs Three Blockchain Agreements Across Diverse Industries
8.507-28GlobenewswireMindChain: The World's First Fully Insured Blockchain Launching Soon
- 8.507-28Newsfilter
MindWave Launches World's First Fully Insured Blockchain
8.505-06NASDAQ.COMApimeds Reaches Settlement with Inscobee, Clearing Path for Merger
APUS 常見問題 —— 由 Alphio AI 解答
Apimeds Pharmaceuticals US, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in developing Apitox, an intradermally administered bee venom-based toxin. It is focused on developing Apitox in the treatment of inflammatory conditions in the United States, specifically osteoarthritis and multiple sclerosis. Its subsidiary, MindWave Innovations Inc, is a provider of institutional digital asset treasury (DAT) solutions. It operates in the Healthcare sector.
Apimeds Pharmaceuticals US Inc is not a good buy right now due to its significant financial losses and poor technical indicators. The current price is $2.68, and the company has reported a staggering net income loss of $35,059,852 in Q1 2026. Additionally, the RSI is at 26.149, indicating that the stock is oversold, but this does not suggest a buying opportunity given the ongoing financial instability.
社群
更多 ↗暫無貼文
註冊或登入後參與討論相關文章
- Are You Buying NVIDIA’s Earnings or Its CEO’s Perfect Image?An Alphio analysis of NVIDIA’s share-price timeline, operating results, governance uncertainty and upcoming earnings.
- Stock Market After the 2026 Midterms: What a Democratic Congress Means for InvestorsDemocrats swept Congress in the 2026 midterms. See how stocks reacted, what history says about post-midterm returns, and which sectors face new risks.
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。